RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

61.93

06-May-25 11:45:36

15 minutes delayed

Stocks

-2.48

-3.85%

Today's range

61.83 - 64.24

ISIN

N/A

Source

NASDAQ

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

23 Oct 2024 07:00:01 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Oct 2024 15:01:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 Sep 2024 15:01:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

26 Aug 2024 07:02:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

26 Aug 2024 07:00:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Aug 2024 15:01:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

06 Aug 2024 06:00:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

31 Jul 2024 08:10:21 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 Jul 2024 07:00:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 Jul 2024 06:30:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 Jul 2024 15:01:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

08 Jul 2024 07:00:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

28 Jun 2024 07:00:14 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 Jun 2024 15:01:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

03 Jun 2024 15:02:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

03 Jun 2024 07:02:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

22 May 2024 03:00:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

09 May 2024 15:01:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

07 May 2024 06:00:00 By Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.